ArticleNanomaterials (Basel, Switzerland)2018
Engineering a 3D-Bioprinted Model of Human Heart Valve Disease Using Nanoindentation-Based Biomechanics.
Article in Nanomaterials (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it, 100 citations in OpenAlex.
- Pooled it
- In vitro model assesses the susceptibility of polymeric scaffolds for material-driven heart valve regeneration to calcification.In vitro models · 2025Article
- Cardiac Tissue Bioprinting: Integrating Structure and Functions Through Biomimetic Design, Bioinks, and Stimulation.Gels (Basel, Switzerland) · 2025Review
- Review
- Calcific aortic stenosis: omics-based target discovery and therapy development.European heart journal · 2025Review
- A Biomimetic Leaflet Scaffold for Aortic Valve Remodeling.Advanced healthcare materials · 2024Article
- Preservation of human heart valves for replacement in children with heart valve disease: past, present and future.Cell and tissue banking · 2024Review
- Intracellular proteomics and extracellular vesiculomics as a metric of disease recapitulation in 3D-bioprinted aortic valve arrays.Science advances · 2024Article
- 3D printed scaffolds based on hyaluronic acid bioinks for tissue engineering: a review.Biomaterials research · 2023Review
- Automatic Photo-Cross-Linking System for Robotic-Based In Situ Bioprinting.ACS biomaterials science & engineering · 2023Article
- Application of Hydrogels in Cardiac Regeneration.Cardiology and therapy · 2023Review
- Bioprinting of Cardiac Tissue in Space: Where Are We?Advanced healthcare materials · 2023Article
- Multiomics of Tissue Extracellular Vesicles Identifies Unique Modulators of Atherosclerosis and Calcific Aortic Valve Stenosis.Circulation · 2023Article
- Transformative Materials to Create 3D Functional Human Tissue Models In Vitro in a Reproducible Manner.Advanced healthcare materials · 2023Article
- Three-Dimensional Bioprinting of Ovine Aortic Valve Endothelial and Interstitial Cells for the Development of Multicellular Tissue Engineered Tissue Constructs.Bioengineering (Basel, Switzerland) · 2023Article
- Network-Guided Multiomic Mapping of Aortic Valve Calcification.Arteriosclerosis, thrombosis, and vascular biology · 2023Review
- Latest Advances in 3D Bioprinting of Cardiac Tissues.Advanced materials technologies · 2022Article
- Advances in three-dimensional bioprinted stem cell-based tissue engineering for cardiovascular regeneration.Journal of molecular and cellular cardiology · 2022Review
- Role of Extracellular Vesicles in the Pathogenesis of Vascular Damage.Hypertension (Dallas, Tex. : 1979) · 2022Review
- Calcific aortic valve disease: from molecular and cellular mechanisms to medical therapy.European heart journal · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 6 institutions in 3 countries.
Funding
Abstract
In calcific aortic valve disease (CAVD), microcalcifications originating from nanoscale calcifying vesicles disrupt the aortic valve (AV) leaflets, which consist of three (biomechanically) distinct layers: the fibrosa, spongiosa, and ventricularis. CAVD has no pharmacotherapy and lacks in vitro models as a result of complex valvular biomechanical features surrounding resident mechanosensitive valvular interstitial cells (VICs). We measured layer-specific mechanical properties of the human AV and engineered a three-dimensional (3D)-bioprinted CAVD model that recapitulates leaflet layer biomechanics for the first time. Human AV leaflet layers were separated by microdissection, and nanoindentation determined layer-specific Young’s moduli. Methacrylated gelatin (GelMA)/methacrylated hyaluronic acid (HAMA) hydrogels were tuned to duplicate layer-specific mechanical characteristics, followed by 3D-printing with encapsulated human VICs. Hydrogels were exposed to osteogenic media (OM) to induce microcalcification, and VIC pathogenesis was assessed by near infrared or immunofluorescence microscopy. Median Young’s moduli of the AV layers were 37.1, 15.4, and 26.9 kPa (fibrosa/spongiosa/ventricularis, respectively). The fibrosa and spongiosa Young’s moduli matched the 3D 5% GelMa/1% HAMA UV-crosslinked hydrogels. OM stimulation of VIC-laden bioprinted hydrogels induced microcalcification without apoptosis. We report the first layer-specific measurements of human AV moduli and a novel 3D-bioprinted CAVD model that potentiates microcalcification by mimicking the native AV mechanical environment. This work sheds light on valvular mechanobiology and could facilitate high-throughput drug-screening in CAVD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.